Hims & Hers Health, Inc. (HIMS) Q1 2026 10-Q (period ending March 31, 2026, filed May 11, 2026) presents a company with negative liquidation recovery across all three MFFAIS metrics: cash liquidation value of -$319.0M, liquid liquidation value of -$287.0M, and operating liquidation value of -$207.0M. The negative equity recovery posture under the liquidation lens reflects the structural asymmetry inherent in HIMS's balance sheet: the company's most valuable assets (platform intangibles, brand, customer relationships, regulatory licenses, and the subscriber base) carry zero recovery in liquidation, while all liabilities remain at face value. The single largest contributor to the negative recovery gap is the $1.0 billion aggregate principal 0% convertible senior notes due 2030, issued May 2025 and carried at face value on wind-up. The $175.0M revolving credit facility (undrawn at period-end per available disclosures) adds incremental secured liability exposure. Operating lease obligations for multiple pharmacy and fulfillment facilities (New Albany OH, Mesa AZ, and others) represent additional face-value liabilities that do not extinguish on wind-up under ASC 842. On the asset side, cash and short-term investments represent the primary source of liquidation recovery. Based on the MFFAIS CLV of -$319.0M versus OLV of -$207.0M, the incremental drag between liquid and operating assets is approximately $112.0M, consistent with PP&E and inventory carrying haircuts applied to pharmacy/compounding facility assets. The filing reports a net loss of $92.1M for Q1 2026, a significant reversal from full-year 2025 net income of $128.4M, driven by the strategic pivot away from compounded GLP-1 products following FDA and HHS regulatory actions directly naming the company. The Eucalyptus proposed acquisition (up to $1.15B consideration, approximately $240M upfront cash at closing expected mid-2026) represents a material forward liquidity event that will compress cash balances and potentially add goodwill and intangibles that carry zero liquidation recovery. The YourBio acquisition closed January 2026 for $150M cash (temporarily drawn on revolver, repaid). FTC investigation (active settlement negotiations as of April 2026) and SEC investigation (opened February 2026) represent unquantified contingent liabilities not separately tagged in XBRL. Filing does not separately tag cash, debt, lease liabilities, goodwill, intangibles, inventory, or PP&E in the TAG_CONTEXT provided; consequently no individual balance sheet line items can be confirmed from XBRL. All balance sheet figures referenced in MD&A and risk factors are used for context in this overview only.
▼ Community Notes